Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases.
Anecortave acetate (5 μl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels[2].
[1]. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S26-34.
[2]. Penn JS, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):283-90.